Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that…

Read the full article here

Source: British Journal of Cancer

Categories: Hem/Oncs, Latest Headlines

Tweets with this article

Pashtoon Kasi MD, MS

RT @ChiaraCrem1: What can we offer our mCRC patients after progression to FOLFOXIRI/bev? Check it out at https://t.co/gyFNdw4Udt So proud o…

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

AbstractPurpose:. To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab as first-line treatment in patients with…

Pashtoon Kasi MD, MS December 6, 2024

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.

Pashtoon Kasi MD, MS December 6, 2024

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the…

Pashtoon Kasi MD, MS November 25, 2024

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Pashtoon Kasi MD, MS November 25, 2024

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Clinical Oncology

Pashtoon Kasi MD, MS November 23, 2024

CCRAN’s Early Age Onset Cancer Symposium – OncoDaily

CCRAN’s Early Age Onset Cancer Symposium / cancer, CCRAN, City of Hope, ctDNA, EAOC24, Early Age Onset Cancer, OncoDaily, Oncology, Orange County, Pashtoon Kasi

Pashtoon Kasi MD, MS November 22, 2024

Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer – OncoDaily

Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer / Biliary tract cancer, cancer, City of Hope, HER2, MedOnc, OncoDaily, Oncology, Pashtoon

Pashtoon Kasi MD, MS November 22, 2024

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

/PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera®…

Pashtoon Kasi MD, MS November 21, 2024

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

/PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera®…

Pashtoon Kasi MD, MS November 21, 2024

Frontiers | Bibliometric analysis of global research trends and prospects on circulating tumor DNA in colorectal cancer

Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China Background: Colorectal cancer…

Pashtoon Kasi MD, MS November 16, 2024

Related Articles